| A Sequential Phase 2/3 Study of APL2 in Patients With Focal Segmental Glomerulosclerosis (NCT07213960) | Apellis Pharmaceuticals, Inc. | 2026-12-01 |
| Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation (NCT07020832) | Apellis Pharmaceuticals, Inc. | 2026-05-18 |
| Study to Evaluate a Pegcetacoplan (Syfovre®) Prefilled Syringe (NCT07214740) | Apellis Pharmaceuticals, Inc. | 2025-10-24 |
| A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio (NCT07215390) | Apellis Pharmaceuticals, Inc. | 2025-06-23 |
| A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration (NCT06161584) | Apellis Pharmaceuticals, Inc. | 2023-09-28 |
| An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis (NCT05809531) | Apellis Pharmaceuticals, Inc. | 2023-05-29 |
| Geographic Atrophy Long-Terms Outcomes Study (NCT06499571) | Apellis Pharmaceuticals, Inc. | 2022-09-01 |
| Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis (NCT05067127) | Apellis Pharmaceuticals, Inc. | 2021-11-12 |
| Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN (NCT04572854) | Apellis Pharmaceuticals, Inc. | 2021-09-07 |
| An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD (NCT04770545) | Apellis Pharmaceuticals, Inc. | 2021-03-04 |
| A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) (NCT04901936) | Apellis Pharmaceuticals, Inc. | 2021-02-04 |
| MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS) (NCT04579666) | Apellis Pharmaceuticals, Inc. | 2020-09-30 |
| A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19 (NCT04402060) | Apellis Pharmaceuticals, Inc. | 2020-05-28 |
| A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With PNH (NCT04085601) | Apellis Pharmaceuticals, Inc. | 2019-08-27 |
| Study to Evaluate the Safety of Intravitreal APL-2 in Patients Diagnosed With Geographic Atrophy (NCT03777332) | Apellis Pharmaceuticals, Inc. | 2018-11-05 |
| Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (NCT03525600) | Apellis Pharmaceuticals, Inc. | 2018-08-31 |
| A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (NCT03525613) | Apellis Pharmaceuticals, Inc. | 2018-08-31 |
| Pegcetacoplan Long Term Safety and Efficacy Extension Study (NCT03531255) | Apellis Pharmaceuticals, Inc. | 2018-08-27 |
| A Phase IIa Study to Assess the Safety, Efficacy, and Pharmacokinetics of Subcutaneously Administered Pegcetacoplan (APL-2) in Subjects With PNH (NCT03593200) | Apellis Pharmaceuticals, Inc. | 2018-08-16 |
| Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies (NCT03453619) | Apellis Pharmaceuticals, Inc. | 2018-02-26 |
| Pegcetacoplan (APL-2) in Neovascular AMD (NCT03465709) | Apellis Pharmaceuticals, Inc. | 2018-02-14 |